Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
Key Highlights
- ➤Five abstracts accepted for Apnimed’s CHEST 2026 presentations
- ➤Three abstracts feature Phase 3 AD109 data in obstructive sleep apnea
- ➤Two late-breakers cover post-menopausal women and hypoxic burden’s blood-pressure response
- ➤AD109 NDA under FDA review with February 28, 2027 PDUFA goal date
- ➤AD109 completed two Phase 3 trials spanning mild to severe OSA
Expert Statements
Patrick Strollo, MD, MS, FCCP; Chair of CHEST panel discussion
“New Medications for Treatment of OSA: The SynAIRgy and LunAIRo Trials”
Kara Dupuy-McCauley, MD, FCCP; Co-Chair of CHEST panel discussion
“New Medications for Treatment of OSA: The SynAIRgy and LunAIRo Trials”
Amir Sharafkhaneh, MD, PhD; Speaker at Apnimed-Sponsored Learning Theater
“Clinical Overview of an Investigational Oral Tablet for OSA”
Dennis Hwang, MD; Speaker at Apnimed-Sponsored Learning Theater
“Clinical Overview of an Investigational Oral Tablet for OSA”
CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that five abstracts have been accepted for presentation at the American College of Chest Physicians' CHEST 2026 Annual Meeting, taking place October 18–21 in Phoenix, Ariz. Three abstracts feature data from the Phase 3 program evaluating the investigational drug AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) in obstructive sleep apnea (OSA), including two late-breaking abstracts that will be presented as a rapid-fire oral presentation and a poster. The other two abstracts present real-world data on the burden of OSA. CHEST will also host a panel discussion on the results of the Phase 3 SynAIRgy and LunAIRo trials and their potential application to OSA management. CHEST 2026 Annual Meeting Presentation Details: Late-Breaking – Rapid Fire Oral Presentation Title: Aroxybutynin and Atomoxetine (AD109) in Post-menopausal Women with Obstructive Sleep Apnea Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope Session Date, Time: Oct 20(th), 2:15-2:19 PM Location: Phoenix Convention Center Exhibit Hall Rapid Fire Area 4D
Get started
Create a free account to read the full story.